GF-107
- Generic Name
- GF-107
A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
Phase 2
Withdrawn
- Conditions
- Intermittent ClaudicationPeripheral Artery Disease
- Interventions
- Other: Placebo
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
- Registration Number
- NCT05618691
- Locations
- 🇺🇸
Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States
A Study of GFH312 in Healthy Subjects
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- GenFleet Therapeutics (Australia) Pty Ltd.
- Target Recruit Count
- 76
- Registration Number
- NCT04676711
- Locations
- 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath